Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.44 |
| ▸ | KCNB1 | Q14721 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CFTR | P13569 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3372019 | 0.87 | KDM4E (0.51) | TDP1KDM4EMRGPRX4ALDH1A1L3MBTL1 | |
| SCHEMBL1968929 | 0.86 | KMT2A (0.49) | KDM4EMRGPRX4ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL27009292 | 0.84 | TDP1 (0.64) | TDP1KDM4EALDH1A1KMT2ATSHR | |
| SCHEMBL9203097 | 0.83 | KDM4E (0.51) | TDP1KDM4EMRGPRX4ALDH1A1L3MBTL1 | |
| SCHEMBL6909317 | 0.81 | TDP1 (0.63) | TDP1KDM4EALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL25794823 | 0.80 | TDP1 (0.62) | TDP1KDM4EALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL7797959 | 0.80 | TDP1 (0.58) | TDP1KDM4EALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL27051378 | 0.79 | TSHR (0.49) | KDM4EMRGPRX4ALDH1A1KCNB1KMT2A | |
| SCHEMBL12818154 | 0.79 | MRGPRX4 (0.46) | TDP1KDM4EMRGPRX4L3MBTL1POLB | |
| SCHEMBL24436789 | 0.78 | CA12 (0.64) | MRGPRX4ALDH1A1SMN1; SMN2CFTRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937659-B1 | CYCLIC N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI AVENTIS (FR) | 2010-11-10 | — | — | EP | disclosed |
| US-7683181-B2 | Cyclic N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, pharmaceutical compositions and methods for the therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-03-23 | — | — | US | disclosed |
| US-7683181-B2 | Cyclic N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, pharmaceutical compositions and methods for the therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-03-23 | — | — | US | disclosed |
| US-7683181-B2 | Cyclic N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, pharmaceutical compositions and methods for the therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-03-23 | — | — | US | disclosed |
| US-20080280959-A1 | CYCLIC N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-11-13 | — | — | US | disclosed |
| US-20080280959-A1 | CYCLIC N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-11-13 | — | — | US | disclosed |
| US-20080280959-A1 | CYCLIC N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-11-13 | — | — | US | disclosed |
| EP-1937659-A1 | CYCLIC N-[1 ,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007039173-A1 | CYCLIC N-[1 ,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039173-A1 | CYCLIC N-[1 ,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280959-A1 | CYCLIC N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE THERAPEUTIC USE THEREOF | PPARD, GPR119, PPARG | TDP1 1873/4885KDM4E 3490/4885MRGPRX4 3016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.